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This work shows that class II-linked humoral lack of response to an antigen can be 
overcome by joint immunization with the antigen and a T-helper cell determinant ( TDh) 
well recognized by class H molecules of a non-responder individual. Thus, SJL/ J  mice 
(H-2S), which are non-responders to the S region of hepatitis B virus surface antigen 
(HBsAg), were rendered responders by joint immunization with a recombinant surface 
antigen, only composed of the S region, and a short synthetic TD h peptide well recognized 
by the H-Y  restriction. By contrast, when this peptide is not recognized as TD h, as in 
BIOM mice (H-2 f restricted and also non-responders to the S region), no humoral response 
could be induced against he S region. These results have important implications for therapy 
and vaccination against hepatitis B virus as well as in enhancing the immunogenicity of
other antigens. 
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It is well established that T-cell help can be provided to 
a hapten by linking this to an amino acid sequence well 
recognized by MHC class II molecules ~6. This sequence, 
referred to as TD h, can also provide help even when not 
covalently linked to the hapten v. These findings uggested 
to us that an individual who fails to respond to a protein 
because of lack of recognition of a TDh within its 
sequence, might be rendered a responder by immunization 
with this 'haptenic' protein and a TD h peptide chosen to 
satisfy the class II restriction of this individual. To test 
this hypothesis we immunized SJL/J (H-2 s) and BI0M 
(H-2 f) mice, two strains of non-responders to the S region 
of hepatitis B surface antigen 8'9, with a recombinant 
surface antigen, only composed of the S region, in 
conjunction with a short synthetic peptide well 
recognized by class II molecules of SJL/J but not by 
those of B 10M. We provide below experimental evidence 
that this simple immunization strategy allows not only 
the manipulation of the humoral response against an 
'haptenic' protein, but is also a convenient way of 
studying which TDh sequences are useful to potentiate 
the inducton of antibodies in the context of a given 
restriction. The results are also discussed in terms of the 
lack of humoral response of a small percentage ofhumans 
following immunization with the hepatitis B vaccine. 
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MATERIALS  AND METHODS 
Antigens 
The antigen used is a recombinant product (expressed 
in yeast cells) from Smith Kline and French, S.A. 
(Engerix-B) and used for vaccination in humans. It is 
composed only of the S region (amino acids 175-400) of 
the HBV surface protein. This antigen will be referred 
to as HBsAg. The TDh peptide FISEAIIHVLHSR 
(designated F1S) corresponds to amino acids 106-118 
from sperm whale myoglobin of proved TDh character 
in Balb/c mice 1° and known to be recognized by class 
II molecules in SJL/J but not in B10M. 
Peptide synthesis 
Peptides were synthesized by the solid-phase method 
of Merrifield 11 using the Fmoc alternative lz. The 
synthesis of TDh peptide FIS was done manually and 
the ninhydrin test of Kaiser et al. 13 used to monitor every 
step. Couplings were repeated if necessary until a negative 
ninhydrin test was attained. FIS was purified by high- 
performance liquid chromatography (h.p.l.c.) on a 
reverse-phase C18 column. The 47 overlapping 14-mer 
peptides (adw zsequence) t4from HBsAg were synthesized 
using a multiple solid-phase peptide synthesizer 15. They 
were used without further purification. 
Immunization experiments 
Groups of 4-week-old SJL/J (H-2 s) or B10M (H-2 f) 
female mice were immunized by intraperitoneal (i.p.) 
injection of 200 #1 of an emulsion obtained by sonication 
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of 100#1 complete Freund's adjuvant and 100 #1 saline 
solution consisting of 1 #g HBsAg in 50#1 Engerix-B 
vaccine suspension and 50 #1 phosphate-buffered saline 
(PBS), or a mixture of 1 #g of this antigen and 60/~g of 
TD h peptide (FIS). They were boosted at day 30 and 45 
with the same dose of antigen in incomplete Freund's 
adjuvant. Mice were bled from the retro-orbital plexus 
on days 30, 45 and 60 after the first injection. 
Titration of antibodies 
Antibodies were titrated by ELISA. Microtitre wells 
were coated by overnight incubation at 4°C with 50 #1 
peptide solutions (20 #g ml- ~ of peptide in 0.1 M sodium 
carbonate buffer) or with 0.1 ~g HBsAg in 50#1 0.1 M 
phosphate buffer, pH 7.0. Wells were then washed three 
times with a solution of PBS. To block non-specific 
antibody binding, the wells were incubated with the 
above buffer but containing 1% powdered milk and 0.1% 
Tween 20 (PBSMT) for 1 h at room temperature. After 
removing the PBSMT, 100 #1 of different serum dilutions 
in PBSMT were added and incubated at 37°C for 1 h. 
Wells were washed three times with PBS and then 
incubated at 37°C for 1 h with a 1/1000 solution of goat 
anti-mouse IgG biotinylated whole antibody (Amersham, 
UK) in PBSMT. After washing three times with PBS, 
wells were incubated with 1/500 dilution of horseradish 
peroxidase-streptavidin n PBSMT (Amersham, UK) at 
3T'C for I h. After washing three times with PBS, the 
colour reaction was started by adding 100 #1 of a solution 
prepared by mixing: 10 ml 0.6% acetic acid (pH 4.7), 7.5/d 
of 33% (w/v) hydrogen peroxide and 100#1 of 40mM 
aqueous solution of ABTS (2,2'-azino-bis (3-ethylbenz- 
thiazoline-6-sulfonic a id). After 60 min the plates were 
read at 405 rim, in a Titertek Multiskan MKII (Flow 
Laboratories). 
IL-2 production assay 
Groups of three mice were immunized at the base of 
the tail and footpads with 1 pg free HBsAg recombinant 
vaccine or with 1 #g of this antigen and 60 #g of FIS in 
complete Freund's adjuvant (1:1). Ten days after the 
primary injection, animals were killed and lymph node 
cells removed. The lymphocytes were then plated on 
96-well plates (Costar) at 5 x l0 s cells/well with RPMI- 
supplemented medium alone (RPMI supplemented with 
10% fetal calf serum, 10mM glutamine, penicillin 
100Uml ~, streptomycin 100mgml 1 and 5x10-SM 
2-mercaptoethanol) or with serial dilutions of HBsAg or 
FIS in the same medium to a final volume of 0.2 ml. 
Supernatants (50 #1) were removed 24 h later and assayed 
for the IL-2 content using the CTL-L bioassay as 
described ~6. Results are presented as stimulation index, 
which is the ratio of the mean (three determinations) 
counts rain 1 incorporated in the presence of antigen to 
the mean (three determinations) counts min-~ obtained 
in the absence of antigen. 
RESULTS 
Induction of anti-HBsAg antibodies 
To study the effect of a free TDh sequence on the 
induction of anti-HBsAg antibodies SJL/J and B10M 
mice were immunized with a mixture of HBsAg (the 
recombinant product from Smith Kline and French, S.A., 
5- 
4-  
[,. 
ee~ 
"< ] 
. . . . . . . . . . . . . . . . . . .  mm--  
HBsAg HBsAg + F IS  HBsAg HBsAg + F |S  
S J I J J  B IOM 
Figure 1 Anti-HBsAg antibodies induced following immunization of 
SJL/J and B10M mice with either ling HBsAg vaccine in Freund's 
adjuvant (sera 181 to 190 or sera 242 to 246 respectively) or a mixture 
of 1 pg HBsAg vaccine and 60pg FIS in Freund's adjuvant (sera 191 to 
199 or sera 247 to 251 respectively). The titres shown are from sera of 
individual animals at day 60 and correspond to the highest serum dilution 
to yield three times the absorbance of a negative serum and are 
expressed as the log of this dilution (D). (*) No antibodies were detected, 
a small bar is shown to indicate that the titration has been carried out 
used for vaccination in humans) and the TDh peptide 
FIS, both emulsified in Freund's adjuvant as stated in 
Methods. We chose these strains because they are 
reported to be non-responders to HBsAg s'9 and it was 
known, from IL-2 production assays, that SJL/J but not 
B10M mice were able to recognize FIS as TDh peptide. 
Figure 1 shows that immunization of SJL/J mice with 
the recombinant HBsAg vaccine alone was unable to 
induce anti-HBsAg antibodies in ten out of ten 
immunized mice. However, immunizations of nine mice 
with the vaccine mixed with FIS in Freund's adjuvant 
rendered HBsAg immunogenic in seven of nine of the 
immunized mice. By contrast, immunization of B10M 
mice using the same strategies did not render any of these 
mice responders to HBsAg. 
Mapping the specificity of anti-HBsAg with synthetic 
peptides 
To map the linear regions of HBsAg, recognized by 
anti-HBsAg antibodies, we synthesized 47 overlapping 
14-mer peptides, encompassing the entire S region (amino 
acids 175-400 of HBV surface protein) and tested them 
by ELISA against he antisera diluted 1/100 and 1/200. 
The recognition was considered positive only if the 
absorbances ofthe ELISA assay for serum dilutions 1/100 
and 1/200 of immunized animals were at least four times 
the average absorbance of the corresponding dilution of 
the serum of a non-immunized animal. The antisera from 
SJL/J mice immunized with 1 #g HBsAg and 60/~g FIS 
were able to recognize several peptides. Most of the tested 
sera recognized peptides 290-303, 295-308 and the 
protein (see Table 1 and Figure 2). 
T-cell response to antigens 
To obtain an insight into which TD h was responsible 
for providing T-cell help to anti-HBsAg antibody 
production cells we immunized SJL/J and B10M mice 
with recombinant HBsAg vaccine alone and with vaccine 
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Table 1 Recognition of 14-mer peptides from the S region of HBsAg and antibody titres induced against HBsAg and FIS 
Sera from mice ~ immunized Anti-HBsAg titre ~ Anti-FIS titre b 
with HBsAg vaccine + FIS (log D) Peptides recognized c (log D) 
194 4.19 290-303 295-308 3.72 
195 3.12 none 3.43 
196 4.28 290-303 295-308 3.00 
197 3.53 290-303 295-308 2.83 
198 4.30 267-280 290--303 295-308 3.47 
199 3.59 285-298 290-303 2.70 
~Each number corresponds to the serum at day 60 of an immunized animal, Only sera with an anti-HBsAg antibody titre >3 are shown 
~Titres were determined by the highest serum dilution to yield three times the absorbance of a negative serum and are expressed as the log of this 
dilution (D) 
CEach peptide is identified by the numbers of the N-terminal and C-terminal amino acids corresponding to its position within the sequence 1-400 of 
the HBV surface protein 
together with FIS in identical proportions to the ones 
used for antibody induction (see Methods). After removal 
of lymph nodes and plating of the lymphocytes, these 
were restimulated with FIS and with HBsAg. Figure3 
clearly shows that in the group of SJL/J mice immunized 
with HBsAg vaccine alone, neither FIS nor HBsAg is 
able to induce IL-2 production, except for a marginal 
signal at the higher dose of HBsAg. However, FIS but 
not HBsAg is able to induce IL-2 in the group of SJL/J 
immunized with the mixture of HBsAg and FIS. By 
contrast, neither of the two groups of B10M-immunized 
mice (with HBsAg alone and HBsAg in conjunction with 
FIS) was able to induce IL-2 production. 
DISCUSSION 
FIS provides T-cell help to SJL/J mice and renders 
them responders to immunization with HBsAg 
Induction of anti-HBsAg antibodies in SJL/J mice was 
only achieved by immunization with the antigen together 
with FIS (Figure I). As has been described before s'9 and 
is shown in Figure 3, the S region of HBsAg is unable to 
induce a T-cell response in SJL/J mice. This explains why 
no humoral response against HBsAg was obtained in the 
group of mice immunized with the vaccine alone. 
However, joint immunization with FIS and HBsAg 
induces a T-cell response specific for FIS. This, together 
with the finding that anti-HBsAg antibodies are induced 
only following joint immunization with vcccine and FIS, 
proves that he T-cell help required to induce the humoral 
response against HBsAg must necessarily come from FIS. 
As suggested previously by this laboratory v, we believe 
that the effect of FIS might be due to direct binding of 
FIS to class II molecules of a physically close B cell 
having recognized an epitope (in the present case from 
HBsAg) via its surface immunoglobulin. Since direct 
binding would be favoured by an excess of FIS at the 
immunization site we have used a high ratio of this 
determinant with respect o HBsAg. We cannot provide 
a clear explanation for the lack of response of two mice 
from Figure 1 to combined immunization with HBsAg 
and FIS. However, it could be tentatively postulated to 
be due to variability between individuals. 
FIS does not provide T-cell help to BIOM mice and thus 
cannot render them responders to immunization with 
HBsAg 
As shown in Figure 1, immunization of B10M mice 
with HBsAg in conjunction with FIS was unable to 
I 2 "1 serum 194 
°t l 
08 
06 
04 
0,2 
O. 0 , , |  . | - | , |  ,I.I . | l  I .I .I .| ,I | .I I .I .| .I.I .l I . . . .  I |  I . I , l , | l  .I m I . I . I  .I,I ,I.I.I I , I  . I . .  
1 2 I serum 196 
"°l lJ ~ 08 06 1 ~ 0.4 ~ 02 00 • I.li,mJl.d.ini,dp.nn.ilai.ni.l.d.nn aili.l.lda.d, , .aliJ.liliiJ.li.di.iidlli,|.ni.il.ii,dl.ll.il,l.li,ii,  
1.2 'l serum 198 
°l, J]l, 
08 
06 
04 
02 
o o , . .I,l.ll I.ll.l.i.l.d.fl,t.l.lll.l.al.l.|..ll.dl I . i  . . . .  I.il,t.l,ll.t.i.dl,l,dl,iJIl.|.t.il.l.l.|,ll I. 
pI~PTIDES 
Figure 2 Recognition of 47 overlapping 14-mer peptides (encompassing 
the entire S region) by anti-HBsAg antibodies induced in SJL/J mice at 
day 60, following immunization with a mixture of FIS and HBsAo 
recombinant vaccine in Freund's adjuvant. Only representative sera 194, 
196 and 198 from Table I are shown. For comparison, the recognition 
of HBsAg by the antisera is also shown. The absorbance values are 
those obtained with the serum dilution 1/100. The solid bars relate to 
the sera of the immunized animals and the open bars to the serum of 
a non-immunized animal. The peptide numbers correspond to the 
position of the amino-terminal amino acid of each peptide with respect 
to the large protein, amino acids 1-400, of the HBV 
render this strain responsive to HBsAg. The experimental 
explanation of this lack of response is given in Figure 3. 
Indeed, the IL-2 production assay shows that, like SJL/J, 
B10M mice are unable to recognize any TD h sequence 
within the recombinant vaccine. Moreover, and in 
contrast o SJL/J mice, the strain B10M is unable to 
recognize FIS as a TDh peptide. Therefore, since FIS is 
not recognized as a TD h peptide, no T-cell help could 
be provided and consequently noanti-HBsAg antibodies 
could be induced. This also corroborates that the role of 
FIS in SJL/J is to provide specific T-cell help for the 
induction of antibodies. 
Mapping the humorai response to HBsAg using 
synthetic peptides 
As shown in Table 1 and Figure 2, peptides 290-303 
and 295-308 were the most commonly recognized among 
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Figure 3 Identification of the antigen responsible for providing T-cell help. Following immunization of SJL/J and B10M mice with HBsAg (vaccine) 
alone (a, c) or with vaccine in conjunction with FIS (b, d), the lymph node cells from these mice were extracted and restimulated in vitro with vaccine 
or with FIS. As shown in (b) for the group of SJL/J mice immunized with a mixture of HBsAg and FIS, a significant stimulation index is only obtained 
after in vitro restimulation with FIS 
the 47 14-mer peptides from the S region of HBV surface 
protein, a result in agreement with the reported 
evidence17 19 that the region 274-331 contains most of 
the B-cell recognition sites of the S region. Since 
antiserum 195 was able to recognize HBsAg but not any 
of the synthetic peptides encompassing this antigen, it 
would seem likely that the antibodies induced in this 
mouse may be directed against a conformational epitope 
of HBsAg not well presented by these short synthetic 
peptides, although it cannot be excluded that this lack 
of recognition could be associated with low affinity 
and/or low antibody titre of immunoglobulins of 
antiserum 195. 
Potential applications of the study 
The strategy of using FIS to potentiate the humorai 
response has proved to be very successful for other 
restrictions in our laboratory. Thus, we have induced 
antibodies in Balb/c mice against more than 100 haptenic 
peptides (data not shown). Also, in five of five peptides 
tested, this procedure was also successful in New Zealand 
white rabbits. We favour this method not only because 
it bypasses the need to couple the TDh peptide to the 
haptenic molecule, or macromolecule, but also, and 
perhaps more importantly, because it avoids the risk of 
inducing unwanted structural changes of relevant 
epitopes of the antigen due to the coupling of the TD h 
sequence. There is, however, a potential disadvantage in
using the strategy of joint immunization with a TD h 
peptide not covalently linked to the hapten, namely the 
possibility of activating unwanted B lymphocytes specific 
for other antigens that might be present at the 
immunization site. Another interesting aspect of the 
strategy of joint immunization of hapten and TD h is that 
it offers the possibility of testing the ability of a TD h 
peptide to provide suitable T-cell help for antibody 
production in the context of a given restriction. 
With respect o vaccination against HBV, it has been 
observed that a small proportion of humans are 
non-responders. This lack of response seems to be due 
to a lack of T-cell help and is associated with the 
restriction HLA-AI, B8 and DR32°'21. Moreover, this 
restriction is also associated with chronic active 
hepatitis 22'23. Our results of joint immunization with FIS 
and HBsAg vaccine obtained in SJL/J mice suggest hat 
a similar strategy might be used to induce anti-HBsAg 
antibodies in those humans who do not respond to 
vaccination 2°'21 with this antigen. However, if the 
purpose of this immunization is to confer long-lasting 
protection against HBV infection, it might be more 
adequate to use a suitable TD h peptide from other 
antigens of the virus to induce memory T cells that could 
be activated following infection with HBV. 
870 Vaccine 1994 Volume 12 Number 10 
We believe that immunization with an antigen in 
conjunction with a suitable TD h peptide to overcome 
non-responsiveness, may make it possible to treat 
chronically infected patients uch as, for instance, those 
infected by hepatitis B virus (HBV). Thus, if a strong 
antibody response against the HBV surface antigen could 
be induced in these patients (like the one observed in 
acute hepatitis B following seroconversion) the HBV 
might be cleared. We are starting experiments to try this 
hypothesis n an animal model. 
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